

# Andrew S Protheroe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2113765/publications.pdf>

Version: 2024-02-01

66  
papers

9,055  
citations

257450

24  
h-index

123424

61  
g-index

67  
all docs

67  
docs citations

67  
times ranked

9805  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	1.6	40
2	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	13.7	173
3	Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). <i>Journal of Clinical Oncology</i> , 2022, 40, 2468-2478.	1.6	22
4	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29
5	The Use of Digital Pathology and Artificial Intelligence in Histopathological Diagnostic Assessment of Prostate Cancer: A Survey of Prostate Cancer UK Supporters. <i>Diagnostics</i> , 2022, 12, 1225.	2.6	3
6	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. <i>European Urology</i> , 2022, 82, 212-222.	1.9	56
7	SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer (mCRPC) – A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.. <i>Journal of Clinical Oncology</i> , 2021, 39, 107-107.	1.6	1
8	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3317-3328.	7.0	14
9	The Potential of Artificial Intelligence to Detect Lymphovascular Invasion in Testicular Cancer. <i>Cancers</i> , 2021, 13, 1325.	3.7	17
10	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. <i>European Urology Oncology</i> , 2021, 4, 456-463.	5.4	18
11	Interferon-Gamma-producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-related Colitis. <i>Gastroenterology</i> , 2021, 161, 1229-1244.e9.	1.3	87
12	Digital Pathology Transformation in a Supraregional Germ Cell Tumour Network. <i>Diagnostics</i> , 2021, 11, 2191.	2.6	8
13	Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12301-12316.	2.0	22
14	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. <i>British Journal of Cancer</i> , 2020, 123, 207-215.	6.4	50
15	Cardiopulmonary resuscitation discussions with patients admitted to acute oncology wards: A national audit of current practice. <i>European Journal of Cancer Care</i> , 2020, 29, e13218.	1.5	1
16	Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study. <i>European Urology</i> , 2020, 77, 759-760.	1.9	1
17	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. , 2020, 8, e000928.		27
18	Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3170-TPS3170.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Case report of oxalate nephropathy in a patient with pancreatic metastases from renal carcinoma. <i>BMC Cancer</i> , 2019, 19, 967.	2.6	0
20	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. <i>Nature Medicine</i> , 2019, 25, 1706-1714.	30.7	407
21	Tumor heterogeneity: does it matter?. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 857-867.	2.4	10
22	Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882080.	2.0	2
23	Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 686-700.	10.7	496
24	Testicular cancer in men with undescended testis: Insights from the Thames Valley Testicular Cancer database. <i>Journal of Clinical Urology</i> , 2019, 12, 274-279.	0.1	0
25	The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: A diagnostic test accuracy systematic review. <i>Cancer Epidemiology</i> , 2019, 59, 15-21.	1.9	25
26	Deep learning for detecting tumour-infiltrating lymphocytes in testicular germ cell tumours. <i>Journal of Clinical Pathology</i> , 2019, 72, 157-164.	2.0	53
27	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. <i>BJU International</i> , 2019, 123, 947-958.	2.5	9
28	A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 406-406.	1.6	8
29	Bilateral Testicular Germ Cell Tumors: A Case-Series From a UK-Based Tertiary Referral Center Over 19 Years. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e513-e516.	1.9	6
30	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002279.	1.2	21
31	Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naïve prostate cancer (LATITUDE): an international, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 194-206.	10.7	126
32	Abiraterone acetate: a potential source of interference in testosterone assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e138-e140.	2.3	5
33	Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) with Haematuria in the Absence of an Upper Urinary Tract Pathology. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1160-1164.	2.0	22
34	Changing Practice Evaluationâ€”Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocolsâ€”Experience From a Supraregional Center. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 240-244.	1.9	8
35	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	5.4	19
36	Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. <i>British Journal of Cancer</i> , 2018, 119, 1044-1051.	6.4	36

#	ARTICLE	IF	CITATIONS
37	RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. PLoS ONE, 2018, 13, e0191890.	2.5	23
38	A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).. Journal of Clinical Oncology, 2018, 36, 4506-4506.	1.6	69
39	Non-germ cell testicular tumours: Follow-up and outcomesâ€™A literature review and experience from a UK tertiary referral centre over 13 years.. Journal of Clinical Oncology, 2018, 36, e16536-e16536.	1.6	1
40	Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors. Clinical Genitourinary Cancer, 2017, 15, 152-156.	1.9	25
41	Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature. Targeted Oncology, 2017, 12, 235-241.	3.6	40
42	Whole-genome sequencing identifies homozygous <i>BRCA2</i> deletion guiding treatment in dedifferentiated prostate cancer. Journal of Physical Education and Sports Management, 2017, 3, a001362.	1.2	9
43	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine, 2017, 377, 352-360.	27.0	1,588
44	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. New England Journal of Medicine, 2017, 377, 338-351.	27.0	1,315
45	Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. Journal of Clinical Oncology, 2017, 35, 1770-1777.	1.6	27
46	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of Clinical Oncology, 2017, 35, 1530-1541.	1.6	54
47	LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.. Journal of Clinical Oncology, 2017, 35, LBA3-LBA3.	1.6	2
48	LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.. Journal of Clinical Oncology, 2017, 35, LBA3-LBA3.	1.6	12
49	Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.. Journal of Clinical Oncology, 2017, 35, 141-141.	1.6	2
50	Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. JAMA Oncology, 2016, 2, 1303.	7.1	67
51	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, The, 2016, 387, 1163-1177.	13.7	1,570
52	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. European Urology, 2016, 69, 924-932.	1.9	22
53	Dismantling the present and future threats of testicular cancer: a grounded theory of positive and negative adjustment trajectories. Journal of Cancer Survivorship, 2016, 10, 194-205.	2.9	21
54	PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours.. Journal of Clinical Oncology, 2016, 34, 430-430.	1.6	5

#	ARTICLE	IF	CITATIONS
55	ToTem: A phase Ib trial of temsirolimus with gemcitabine and cisplatin.. Journal of Clinical Oncology, 2016, 34, e16032-e16032.	1.6	0
56	SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma. European Urology, 2015, 67, 599-602.	1.9	29
57	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nature Communications, 2015, 6, 6336.	12.8	100
58	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	27.0	1,796
59	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. Journal of Clinical Oncology, 2015, 33, 51-57.	1.6	268
60	Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncology, The, 2014, 15, 975-985.	10.7	172
61	Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial.. Journal of Clinical Oncology, 2014, 32, 5079-5079.	1.6	1
62	Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 102-102.	1.6	4
63	Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.. Journal of Clinical Oncology, 2014, 32, 14-14.	1.6	4
64	Changing prognosis of renal cell carcinoma: a single-centre experience over 25 years. Journal of Clinical Urology, 2013, 6, 119-124.	0.1	0
65	Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study.. Journal of Clinical Oncology, 2013, 31, 4508-4508.	1.6	4
66	Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nature Clinical Practice Oncology, 2005, 2, 68-69.	4.3	2